Fig. 1: Comparative analysis of cell cycle-related gene set enrichment scores and the correlation between cell cycle-related pathway and drug response.

A The scaled enrichment scores from single-sample gene set enrichment analysis (ssGSEA) for three cell cycle-related hallmark gene sets (“HALLMARK_G2M_CHECKPOINT,” “HALLMARK_E2F_TARGETS,” and “HALLMARK_MITOTIC_SPINDLE”) were compared across three groups: non-CK, TP53^mut CK and TP53^wt CK. Each row represents a different cohort, and each column represents a different gene set. B Drug sensitivity of the non-CK, TP53^wt CK, and TP53^mut CK groups to elesclomol, JAK inhibitors (ruxolitinib, S1312, and AZD1480), and the STAT3 inhibitor (S31-201). Significance was assessed using the Mann–Whitney test. C Scatter plots showing the correlation between the enrichment score of the “HALLMARK_MITOTIC_SPINDLE” gene set and the AUC for three drugs: (left) cytarabine, (middle) sorafenib, and (right) elesclomol.